Epilepsy in the Elderly  by Chen, Lu-An et al.
at SciVerse ScienceDirect
International Journal of Gerontology 6 (2012) 63e67Contents lists availableInternational Journal of Gerontology
journal homepage: www.i jge-onl ine.comReview Article
Epilepsy in the Elderlyq
Lu-An Chen, Shih-Jung Cheng, Shuo-Bin Jou*
Department of Neurology, Mackay Memorial Hospital, Taipei, Taiwana r t i c l e i n f o
Article history:
Received 8 September 2011
Accepted 22 February 2012
Available online 12 June 2012
Keywords:
age-speciﬁc,
anticonvulsants,
seizure,
tolerabilityq All contributing authors declare no conﬂict of int
* Correspondence to: Dr Shuo-Bin Jou, Departm
Memorial Hospital, Number 92, Section 2, Zhongsh
District, Taipei 10449, Taiwan.
E-mail address: shuobinjou@gmail.com (S.-B. Jou)
1873-9598/$ e see front matter Copyright  2012, Ta
doi:10.1016/j.ijge.2012.05.013s u m m a r y
Elderly people are the largest and continuously fastest growing population among patients with epilepsy.
Elderly patients with epilepsy are very different from other age groups in many respects and clinicians
shouldn’t treat them in the same way as younger adults. Accurate diagnosis of epilepsy in the elderly is
much more difﬁcult and atypical manifestations and misdiagnoses are certainly not the exception.
Syncope is probably the most important differential diagnosis. High clinical suspicion and proper
investigation are the best tools for prompt diagnosis. Etiologies of late-onset epilepsy are mainly
symptomatic and cerebrovascular diseases are the most common causes in this age group, followed by
degenerative diseases such as Alzheimer’s disease. It is appropriate to consider starting antiepileptic drug
(AED) treatment at the ﬁrst-ever seizure in elderly patients who have remote symptomatic causes such
as stroke and dementia. According to the high recurrence rate of seizure and the good response to AEDs
in elderly patients, the proper choice from various AEDs for seizure control is very important. Decision-
making for AED choice depends on many different factors, including pharmacological properties, efﬁcacy,
tolerability from side effects, drug interactions, and medical comorbidities. The newer AEDs with lesser
adverse effects and fewer drug interactions appear to be reasonable treatment options for elderly
patients. However, more evidence from clinical trials in this speciﬁc age group is warranted.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
One in every 26 people will suffer from epilepsy during their
lifetime1, and many of these are elderly people. Elderly people
(aged more than 65 years) have the highest prevalence and inci-
dence of epilepsy, almost twice that observed in children, and the
prevalence keeps growing along with advancing age. In the
subgroup of the oldest aged, more than 80 years, the prevalence of
epilepsy is even triple the rate of children2,3. With the continued
aging of the worldwide population, it is not surprising that clini-
cians are facing more and more elderly patients with epilepsy. Not
only physical health but also mental health is negatively inﬂuenced
by epilepsy in this age group4. Aged epileptic patients suffer from
greater perception of stigma, poorer psychosocial consequences
and larger impact on quality of life5,6. Meanwhile, elderly patients
differ from younger adults in many aspects. Management of elderly
patients with epilepsy requires unique considerations from youngerest.
ent of Neurology, Mackay
an North Road, Zhongshan
.
iwan Society of Geriatric Emergenadults in diagnosis, differential diagnosis, etiology, prognosis and
treatment.
References for this review article were identiﬁed through
searches of PubMed until June 1, 2011, using the terms “epilepsy”,
“seizure”, “elderly”, “anticonvulsant” and “aged”. Only papers
published in English were reviewed. The ﬁnal reference list was
based on relevance to the topics in this review article.1.1. Challenges of diagnosing epilepsy in the elderly
Prompt diagnosis of seizure in elderly patients is much more
challenging than in young adults owing to high frequency of
comorbidity, atypical presentations of seizure disorders, and low
possibility of detecting interictal epileptiform activity on electro-
encephalogram exam7. There are many conditions that can mimic
seizure including: transient ischemic attack, transient global
amnesia, syncope, cardiac arrhythmia, sleep disorder etc. High
prevalence of cardiovascular comorbidities and pre-existing
neurological diseases including stroke and other neurodegenera-
tive processes further complicate diagnostic considerations.
Underdiagnosis of epilepsy results in risk a seizure attack and
physical injury. However, overdiagnosis of seizure may lead to not
only unnecessary long-term exposure to antiepileptic drugs butcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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diseases. Among the long list of differential diagnosis, syncope is
probably one of the most frequently encountered and confusing
conditions. Syncope is lack of cerebral perfusion that is mainly
caused by orthostatic hypotension, cardiovascular problems,
arrhythmia or exaggerated vasovagal reﬂex. Several clinical clues
provide useful differentiation between these two conditions, but
the border is relatively vague in the elderly. Syncope in elderly
people can present without typical warning symptoms or obvious
posture change usually identiﬁed in younger patients. Prolonged
and slower recovery of consciousness in elderly syncope patients
might also make physicians confused with the post-ictal state8. On
the other hand, seizure in the elderly patient often presents with
somewhat atypical features. Classic aura, automatisms or general-
ized tonic-clonic convulsions are less common9. Lack of speciﬁc
clinical signals can lead to diagnostic difﬁculty in elderly patients
having a new onset of seizure. Data from a Veteran Affairs study
revealed only 73% of patients eventually diagnosed with epilepsy
were clinically suspected at the initial evaluation10. Thosewho have
under-recognized epilepsy might be left untreated leading to delay
of delivery of an antiepileptic drug, even for years11. Subtle gener-
alized convulsive status epilepticus or non-convulsive status epi-
lepticus may be left unnoticed as an acute confusion state,
metabolic encephalopathy, memory disturbance or psychosis
unless revealed by electroencephalogram (EEG) recording12. EEG is
a routine test for patients suspected of having seizure disorders, but
there is substantially lower prevalence of interictal epileptiform
activity in late-onset epilepsy patients than thosewho already have
pre-existing epilepsy. A study showed that interictal epileptiform
activity was present on the ﬁrst EEG in 35% of patients with pre-
existing epilepsy, but only in 26% of patients who had ﬁrst
seizure after the age of 6013. Non-speciﬁc ﬁndings or even normal
results of routine EEG exam is not uncommon in elderly patient
who actually have seizure disorders7. Long-term video EEG moni-
toring may help those unconﬁrmed cases14. A short diagnostic
algorithm has been proposed for suspected seizure in the elderly15.
The algorithm was composed of seven clinical and EEG criteria
(three major criteria and four minor criteria) with sensitivity and
speciﬁcity of 84.8% and 88.6%, respectively. However, the algorithm
is not yet validated prospectively and still needs further evaluation.
Clinical suspicion and appropriate EEG study remain the most
practical tools to make accurate diagnosis of seizure disorder in the
elderly.
1.2. Different manifestations of epilepsy between young adults and
elderly patients
There are many important differences in the features of epilepsy
between young adults and elderly patients. First of all, the most
common seizure type presenting in elderly patients is the partial
seizure2, while young patients present much more frequently with
generalized seizures. Of the two subtypes of partial seizures,
complex partial seizures, with or without secondary generalization,
are even more common in elderly patients than simple partial
seizures11. It is indeed true that an elderly patient can be witnessed
having a generalized tonic-clonic seizure, but it is probably more
likely to be a secondary generalized convulsion from a previously
unrecognized partial-onset seizure10,16. The clinical manifestations
of partial seizures in elderly patients vary a lot and are less typical
than originally thought. For example, elderly patients tend to have
less auras and seizure symptomology, which is also less speciﬁc
compared to young adults. Furthermore, despite the large propor-
tion of complex partial seizures in elderly epileptics patients, classic
automatisms are usually not identiﬁed during the ictal phase (such
as oroalimentary and hand automatism which are stronglysuggestive of temporal lobe seizures in young adults). Brief dizzi-
ness, motionless staring followed by short periods of confusion or
consciousness disturbance is probably the only manifestation of
complex partial seizure in elderly people10. The non-speciﬁc
symptoms of auras and lack of typical automatisms lead to more
difﬁculty for physicians inmaking an accurate diagnosis. During the
post-ictal period, elderly patients suffer from longer post-ictal
confusion state compared to young adults, lasting for hours, days,
or even weeks17. Not surprisingly, elderly patients are more
vulnerable to injury as a consequence of seizures. An unprotected
fall can lead to serious multiple bone fractures or head injury.
Mortality rate of epilepsy in this age group remains high, especially
in those who suffer from status epilepticus17,18.
Apart from the clinical presentations, the etiologies of elderly
patients with epilepsy are also quite different from children and
young adults. Epileptic seizures can be classiﬁed as symptomatic,
idiopathic, or cryptogenic. Correct identiﬁcation of the etiology of
new onset of seizure in the elderly leads to proper management.
The most common cause of seizure in the elderly is symptomatic
and cerebrovascular diseases account for 40e50% of identiﬁable
causes10,11. Patients with cerebral infarction are at 17 times higher
risk of developing epilepsy compared to the general population19.
The cumulative incidence of developing initial late seizures after
stroke was 3.0% by 1 year, 4.7% by 2 years, 7.4% by 5 years, and 8.9%
by 10 years19. Degenerative diseases such as Alzheimer’s disease
are also associated with high risk of late onset of epilepsy. There is
a six-fold increased risk of unprovoked seizure in demented
patients compared to the controls, after adjusting for age and sex20.
Even patients with only mild or early Alzheimer’s disease have
increased cumulative incidence of unprovoked seizure up to 8% at
7-year prospective follow-up21. Other etiologies such as brain
tumor, central nervous system infection22, and traumatic brain
injury occur at any age, and still contribute to substantial cases in
the elderly just like other age groups23. Those elderly patients
without identiﬁed etiology of epilepsy should be still regarded as
“cryptogenic” even though the underlying causes cannot be
determined16. Despite thorough investigation, one-third of elderly
epilepsy patients still remain “cryptogenic”11.
Epilepsy, by deﬁnition, tends to have recurrent unprovoked
seizures. The estimated recurrence risk after the ﬁrst unprovoked
seizure has ranged from 23% to 71% according to different study
designs24. Elderly patients diagnosed with ﬁrst unprovoked seizure
have even higher rates of recurrence and a trend to developed
epilepsy25, especially in post-stroke patients26. Studies have shown
that recurrence rates in elderly patients range from 40% to 90% after
ﬁrst seizure if left untreated10. The possible explanation of high
recurrence rate in late onset epilepsy is the presence of remote
underlying brain focal pathology, which tends to develop more
epileptogenicity resulting in recurrent seizures. The risk of seizure
recurrence is a major factor for deciding when to start treating
patients with antiepileptic drugs (AEDs). Although AEDs are not
usually recommended for only a single unprovoked seizure in the
general population, it may be appropriate and reasonable to start
treatment as from the ﬁrst seizure in elderly patients when
considering the high risk of recurrence and possibility of a serious
subsequent second attack16,27,28. Thus considerations of AED
treatment in elderly patients with epilepsy are extremely impor-
tant because they can receive empirical treatments as from the ﬁrst
unprovoked seizure. Many elderly patients have become long-term
users of AEDs despite being seizure-free for years because the
underlying factors (e.g., cerebrovascular diseases, neurodegenera-
tive process etc.) of developing epilepsy are not likely to disappear
in the future. The decision whether or not to start AEDs after
a single unprovoked seizure should depend on risk stratiﬁcation of
recurrence29, underlying neurological deﬁcit, and the patient’s (as
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suffered frommore than onewell-documented unprovoked seizure
should generally receive AEDs just like patients in other age groups.
1.3. Special issues for treatment of elderly epilepsy patients
AEDs play the main role in treatment of elderly patients with
epilepsy. Generally speaking, AEDs are effective in approximately
60% of all epilepsy patients30. But AEDs can be more effective and
have even higher response rates up to 80% in the subgroup of late
onset epilepsy31,32. However, the aim of AED treatment is not
simply to reach a seizure-free state. The goals of AED treatment
should be both excellent efﬁcacy and minimal adverse response,
thus resulting in improvement of quality of life. On the other hand,
AED treatment in the elderly patient group raises concerns
regarding some special issues such as altered pharmacokinetics and
pharmacodynamics related to age-associated changes, low tolera-
bility and high incidence of adverse effects, complicated medical
comorbidities, and multiple drugedrug interactions. The decision-
making aspect of AED choice in elderly patients is extremely
important.
Despite the growing prevalence of elderly epilepsy patients,
evidence from double-blind randomized controlled trials of this
age group still remain inadequate. It is not surprising that elderly
individuals are easily excluded from clinical trials due to underlying
comorbidities, polypharmacy or relatively short life expectancy.
However, elderly patients should never be treated the same as
young adults.
1.4. Pharmacological changes of AEDs in the elderly
Age-related physiologic changes alter pharmacodynamics and
pharmacokinetics of AEDs. The drug absorption kinetics is affected
by gastrointestinal change related to aging33. The protein binding
rate, distribution, elimination and clearance of AEDs change
according to the decline of liver and renal function. Phenytoin for
example still remains a commonly used AED even in elderly
patients. Phenytoin has several pharmacological disadvantages
including steep nonlinear kinetics and hepatic enzyme induction16.
Data from pharmacokinetic analysis in old patients taking
phenytoin revealed aging is associated with a gradual decline in
AED clearance34. Furthermore, as serum albumin level falls grad-
ually with each decade of age35, relatively lower phenytoin doses
and lower plasma concentrations can be adequate for satisfactory
seizure control in elderly patients36,37. The therapeutic window
needs to be narrowed down in elderly patients. Valproic acid,
another high albumin binding AED, also has increased fractions of
unbound free-form in elderly patients38. Measurement of serum
AED concentrations can be valuable in determining dosage in
epileptic patients. But ﬂuctuating serum concentrations were
observed in elderly individuals despite constant dosage39. Depen-
dence on total drug levels alone may also lead to ignorance of
toxicity of unbound free-form AEDs. Newer generation AEDs,
although less protein-bound, are still greatly inﬂuenced by age-
related changes in pharmacokinetics. The oral clearance of new
generation AEDs in elderly is reduced 10e50% compared to young
adults40. “Start low and go slow” still remains the rule of thumb of
any initial AED treatment in this age group.
1.5. Efﬁcacy and evidence
Seizure reduction and seizure freedom determine quality of
life41. Variable AEDs can be divided into old drugs (phenobarbital,
phenytoin, carbamazepine and valproic acid etc.) and newer drugs
(lamotrigine, gabapentin, oxcarbazepine, topiramate, levetiracetametc.). Different countries have their own guidelines and the
recommendations vary between them. But generally speaking,
there are no differences in efﬁcacy between the old drugs and
newer drugs. Partial seizure, for example, is already mentioned as
the most common seizure type in elderly patients. Many double-
blind controlled studies have shown that new drugs are equiva-
lent to old drugs in controlling seizures but with less side effects
and better tolerability42e44. The American Academy of Neurology
(AAN) has equal preference between old drugs (carbamazepine,
phenytoin, valproic acid, phenobarbital) and newer drugs (lamo-
trigine, gabapentin, oxcarbazepine, topiramate) as level A recom-
mendation in newly diagnosed partial epilepsy45. However, the
AAN only made recommendations in the general population with
partial seizure without mention of special considerations in elderly
patients. The UK National Institute for Health and Clinical Excel-
lence (NICE) guidelines also didn’t recommend any preference
between old and new AEDs in treatment of partial seizure46.
Although clinical usage of newer AEDs is becoming more attractive
for various reasons, older AEDs still occupy a substantial proportion
of treatment choices in real life practice, even in elderly
individuals47.
There are only a few clinical trials targeted speciﬁcally to elderly
patients with epilepsy. The ﬁrst trial comparing old and new AEDs
in elderly patients was the UK Lamotrigine Study, which was
a double-blind randomized study comparing lamotrigine and car-
bamazepine in 150 newly diagnosed elderly patients with epilepsy.
These two AEDs had similar efﬁcacy in seizure control but lamo-
trigine seemed to have fewer side effects such as rash and
somnolence, and thus remained at a higher retention rate48.
Another landmark trial was the Veterans Affairs Cooperative 428
study enrolling 593 new onset elderly epilepsy patients. Carba-
mazepine was compared with two new drugs, lamotrigine and
gabapentin as initial monotherapy. No signiﬁcant differences in
seizure-free rates were found in a 12-month observation period,
indicating similar efﬁcacy in seizure control among these AEDs49.
But early discontinuation of AEDs occurred signiﬁcantly more often
in carbamazepine than either lamotrigine or gabapentin owing to
higher incidence of adverse effects. Based on the only class I study
and other randomized control trials, the International League
Against Epilepsy (ILAE) listed both lamotrigine and gabapentin as
level A recommendations in elderly adults with partial-onset
seizures50. Carbamazepine was rated as level C alternative choice
according to its similar efﬁcacy but inferior retention rate. However,
the higher dropout rate of carbamazepine can be at least partially
explained by the use of immediate-release form and higher dosage.
A multi-center randomized double-blind controlled trial re-
evaluated the effectiveness between lamotrigine and sustained-
release carbamazepine in 185 elderly epilepsy patients51. The
differences of retention rate became less prominent. As there are no
signiﬁcant differences in efﬁcacy among all the available AEDs for
seizure control, the choice depends heavily on the side effect
proﬁles, comorbidities and drugedrug interactions.
1.6. Tolerability and side effects of AEDs in the elderly
AEDs tolerability is at least as important as its efﬁcacy. Patients
under good seizure control may withdraw from AEDs simply
because of their unbearable side effects. Not surprisingly, elderly
patients are more sensitive and vulnerable to AED’s adverse effects,
especially central nervous system side effects such as dizziness,
sedation, gait disturbance etc52. AED adverse effects in elderly
patients are common, serious, yet can be preventable53. In the
previously mentioned clinical trials48,49, lamotrigine and gaba-
pentin were better tolerated than carbamazepine thus becoming
the priority in treating geriatric partial epilepsy.
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predicting treatment failure. New-generation AEDs have better
safety proﬁles than older AEDs and can be reasonably applied as
initial treatment of epilepsy in the elderly. Judging from this,
phenytoin seems to be an unfavorable choice according to phar-
macological disadvantages and higher incidence of adverse
effects16. Despite the growing evidence and recommendations for
the applications of new AEDs as better options, phenytoin is
currently still widely prescribed in 67% of new onset epilepsy in
elderly individuals54. Slow translation of guidelines into clinical
practice may be partially caused by high cost and unfamiliarity of
new AEDs, especially for non-neurologists55. However, use of new
AEDs has increased signiﬁcantly year-on-year54 and safety and
tolerability data of new AED in late onset epilepsy are being pub-
lished increasingly. Apart from the previously mentioned lamo-
trigine and gabapentin, other new AEDs such as oxcarbazepine56,57,
levetiracetam58e61, and topiramate62 (low dose 50 mg/day63) are
also safe and reasonable choices for elderly patients.
1.7. Drugedrug interactions and comorbidities
Elderly epilepsy patients require AEDs that neither interact with
their co-medications nor worsen their coexistent medical illnesses.
Polypharmacy is extremely common in elderly epilepsy patients,
and leads to non-adherence to AEDs among more than 40% of this
patient group64. Non-compliance of AEDs causes increased cost and
hospitalization, risk of injury, and triples the mortality risk65. Pol-
ypharmacy is quite ordinary especially in patients with cerebro-
vascular disease, the most common underlying cause of late onset
epilepsy. These patients usually take anticoagulants, antihyper-
tensives, statins, antiarrhythmic medications and psychotropic
agents, which are all easily inﬂuenced by enzyme inducing or
inhibiting AEDs. Geriatric patients are undoubtedly vulnerable to
drugedrug interactions. Potential drug interactions are seen in
nearly half of elderly epilepsy patients and mostly seen in
phenytoin between cardiovascular medications or psychotropic
agents66. The newer AEDs without signiﬁcant drug interactions
(such as gabapentin, levetiracetam, pregabalin or low-dose lamo-
trigine) may be suitable to minimize this problem67e69.
Besides the age dependent physiologic decline in renal and
hepatic function in healthy elderly, prevalence of chronic liver and
kidney diseases also increase in this age group. Old AEDs are
generally hepatic metabolized and high albumin-binding thus
potentially cause exacerbation of pre-existing liver disease or
increased the AED’s toxicity70. Dose reduction or shifting to renally
excreted new AEDs (such as gabapentin, topiramate, and levetir-
acetam) becomes the treatment of choice in chronic liver diseases.
On the other hand, these renally excreted and low protein-bound
AEDs need dose adjustment in chronic kidney disease and some-
times additional doses after hemodialysis71. Lower dosage and
slower titration rate are generally recommended in patients with
these comorbid conditions.
2. Conclusions
As the population ages, it is likely that clinicians will face more
and more elderly patients with epilepsy both now and in the
future. Epilepsy in the elderly is very different from younger
adults in many aspects, from etiology and diagnosis, to treatment,
while recognition of these important differences and under-
standing of special issues in the elderly improve our clinical
practices. Reasons for choosing particular AEDs for elderly
patients with epilepsy are inﬂuenced by many factors, including
evidence from clinical studies and guidelines, unique properties of
various AEDs and underlying diseases of patients. As there are nosigniﬁcant differences in efﬁcacy among the available AEDs,
treatment considerations are therefore heavily dependent on
adverse effect proﬁles, drug interaction and underlying comor-
bidities. Obviously there is still no one best AED for elderly
patients with epilepsy. Individualized choice of AEDs for every
elderly patient having a different situation remains the golden
rule in clinical practice.
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